Epilepsy represents a common chronic neurological disorder with a high disability rate, affecting more than 50 million people worldwide [1]. However, the pathogenesis of epilepsy has not yet been fully elucidated. And the treatment of epilepsy still faces many difficulties. The current anti-epileptic drugs are more of a blockage of the disease process and do not directly target the cause of seizures. So most of the seizures are still recurrent and cannot be cured at the root after being controlled by drugs.

MicroRNA (miRNA) is a non-coding ribonucleic acid, about 19 - 22 nt in length, which plays an important role in the post-transcriptional regulation of gene expression [2] [3]. It has been found that some miRNAs are involved in the regulation of epileptogenesis and maintenance, which exert neuroprotective effects through various mechanisms involving apoptosis, synaptic regulation, etc [4]. For example, MiR-34a inhibits neuronal apoptosis in epilepsy by inhibiting activated caspase-3 protein [4]. MiRNA-344a may have a minor regulatory effect on epilepsy-induced cortical apoptotic signaling pathways, but the specific target is unknown. MiR-134 inhibitor exerts neuroprotective effects by upregulating hippocampal limk1 expression and downregulating cofilin expression in SE rats [5].

Bibliometrics are increasingly being used for research evaluation methodology, which offers a quantitative approach to analyzing academic literature in a specific field [6] [7]. But there is no bibliometric study of microRNAs in epilepsy. So we aim to examine trends and hotspots of microRNAs in epilepsy through the past 10-year publications to guide the research directions.

All publications were from Web of Science Core Collection of the Web of Science (WOS). Retrieval Strategy was TS = (“microRNA” and “epilepsy”). The timespan ran between 2001-01-01 and 2021-12-31. Only articles and reviews were included. Meeting Abstracts, Editorial Materials, Letters, Book Chapters, Corrections, Retractions, Data Papers, Proceedings Papers and Retracted Publications were excluded. Then HistCite, VOS viewer and excel were used for bibliometric analysis (Figure 1).

The 10-year cross-sectional study found that the number of annual publications climbs gradually, peaking in 2020. Moreover, Most of research in this field has been done by China, USA, Ireland, and other Western countries. Extensive international cooperation between countries existed. Last, miR-146a, miR-155 and miR-132 were the most studied microRNA.

miR-146a is increased in hippocampus in rat model of epilepsy and patients with epilepsy (PWD) [4] [8] [9] [10]. In addition, miR-146a was found up-regulated in serum of PWD and may be a biomarker for epilepsy. Evidence from clinical studies also suggests that the rs57095329 polymorphism in the promoter region of miR-146a is associated with genetic susceptibility and seizure frequency of drug-resistant epilepsy [11] [12] [13]. Inflammatory response plays a crucial role in epilepsy [14] [15]. miR-146a can exert a pro-inflammatory effect via forming a miR-146a-CFH-IL-1 beta loop circuit and then leads to cause exacerbation of epilepsy [16]. In refractory epilepsy, suppressing the miR-146a gene can reduce pathogenic alterations while also improving medication resistance via regulating HMGB1/TLR4/NF-kB signaling pathway [17]. In addition, silencing miRNA-146a can reduce neuronal injury via down-regulating Notch-1 in the lithium chloride-pilocarpine rat models [18].

miR-155 exerts a crucial role in controlling inflammatory responses and apoptosis signaling associated with epilepsy [19] - [26]. miR-155 expression is elevated in model of epilepsy and PWD [19] [22] [23] [25] [27]. On the one hand, miR-155 may regulate neuroinflammatory responses by interacting with TNF-α [22]. On another hand, this miRNA can also induce neuronal apoptosis via regulating Sestrin-3, BDNF and PI3K/Akt/mTOR signaling pathway [23] [24] [25].

In the dynamic control of neuronal development, maturation, and functioning, miR-132 plays a role in axon growth, neural migration, and plasticity [28]. MiR-132 was upregulated in the Three Stages (The latent stage, acute and chronic stages) of MTLE (Mesial Temporal Lobe Epilepsy) and in Immature Rats Children with MTLE [29]. In vitro and in vivo studies showed that miR-132 could promote epileptogenesis and progression of epilepsy by modulating dendritic spines, reducing neuronal apoptosis, and altering neuronal excitability [30] [31] [32]. Moreover, Bioinformatics suggests that miR-132 not only promotes primary epilepsy, but it also promotes glioma-induced epilepsy [33].

microRNAs in epilepsy remain an active field, with a large number of microRNAs shown to be associated with epilepsy. Especially, miR-146a, miR-155 and miR-132 can cause exacerbation of epilepsy and are hot spots for research in epilepsy. miR-155 regulates inflammatory responses and apoptosis signaling associated with epilepsy. miR-146a can induce inflammation, neuronal injury and medication resistance. Modulating dendritic spines, reducing neuronal apoptosis, and altering neuronal excitability may be responsible for miR-132 exacerbating epilepsy. More and more microRNAs associated with epilepsy will be found and mechanisms related to epilepsy will be eluted in the future.

This work was supported by funding from Affiliated Hospital of North Sichuan Medical College (No. 2021LC008).

The authors declare no conflicts of interest.

Wang, S.L. and Jiang, G.H. (2022) Trends and Hotspots of microRNAs in Epilepsy: A 10-Year Cross-Sectional Study. Open Access Library Journal, 9: e8650. https://doi.org/10.4236/oalib.1108650